Share-based Payment Arrangement, Expense of PDS Biotechnology Corp from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PDS Biotechnology Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • PDS Biotechnology Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,246,485, a 30% decline year-over-year.
  • PDS Biotechnology Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $4,592,584.
  • PDS Biotechnology Corp annual Share-based Payment Arrangement, Expense for 2024 was $6,848,193, a 10% decline from 2023.
  • PDS Biotechnology Corp annual Share-based Payment Arrangement, Expense for 2023 was $7,614,321, a 47% increase from 2022.
  • PDS Biotechnology Corp annual Share-based Payment Arrangement, Expense for 2022 was $5,196,156, a 28% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PDS Biotechnology Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,592,584 $1,246,485 -$531,787 -30% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $5,124,371 $448,029 -$1,347,693 -75% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $6,472,064 $1,253,882 -$376,129 -23% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $6,848,193 $1,644,188 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $1,778,272 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,795,722 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $1,630,011 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2022 $5,196,156 $1,374,232 -$299,243 -18% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $5,495,399 $1,344,350 -$357,412 -21% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $5,852,811 $1,348,601 +$907,003 +205% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $4,945,808 $1,128,973 +$871,351 +338% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2022 2022 Q1
Q4 2021 $4,074,457 $1,673,475 +$1,542,051 +1173% 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $2,532,406 $1,701,762 +$1,571,970 +1211% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $960,436 $441,598 +$395,485 +858% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $564,951 $257,622 +$132,630 +106% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $432,321 $131,424 -$113,972 -46% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $546,293 $129,792 +$9,586 +8% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $536,707 $46,113 +$27,533 +148% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $509,174 $124,992 -$2,629,879 -95% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $3,139,053 $245,396 +$86,782 +55% 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $3,052,271 $120,206 +$78,515 +188% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3
Q2 2019 $2,973,756 $18,580 -$26,047 -58% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $2,999,803 $2,754,871 +$2,747,856 +39171% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q4 2018 $251,947 $158,614 -$1,387,085 -90% 01 Oct 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q3 2018 $1,639,032 $41,691 -$1,529,223 -97% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $3,168,255 $44,627 -$1,535,896 -97% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2019 2019 Q2
Q1 2018 $4,704,151 $7,015 -$1,478,690 -100% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $6,182,841 $1,545,699 +$269,955 +21% 01 Oct 2017 31 Dec 2017 10-K 21 Feb 2019 2018 FY
Q3 2017 $5,912,886 $1,570,914 +$337,883 +27% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $5,575,003 $1,580,523 +$199,529 +14% 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 $5,375,474 $1,485,705 +$70,404 +5% 01 Jan 2017 31 Mar 2017 10-Q 01 May 2018 2018 Q1
Q4 2016 $5,305,070 $1,275,744 -$56,996 -4.3% 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2018 2017 FY
Q3 2016 $5,362,066 $1,233,031 +$621,153 +102% 01 Jul 2016 30 Sep 2016 10-Q 01 Nov 2017 2017 Q3
Q2 2016 $4,740,913 $1,380,994 +$797,479 +137% 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2017 2017 Q2
Q1 2016 $3,943,434 $1,415,301 +$1,044,130 +281% 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q4 2015 $2,899,304 $1,332,740 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
Q3 2015 $611,878 +$331,888 +119% 01 Jul 2015 30 Sep 2015 10-Q 01 Nov 2016 2016 Q3
Q2 2015 $583,515 01 Apr 2015 30 Jun 2015 10-Q 03 Aug 2016 2016 Q2
Q1 2015 $371,171 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q3 2014 $279,990 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3

PDS Biotechnology Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,848,193 -$766,128 -10% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $7,614,321 +$2,418,165 +47% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $5,196,156 +$1,121,699 +28% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $4,074,457 +$3,642,136 +842% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $432,321 -$2,706,732 -86% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $3,139,053 +$2,887,106 +1146% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $251,947 -$5,930,894 -96% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
2017 $6,182,841 +$877,771 +17% 01 Jan 2017 31 Dec 2017 10-K 21 Feb 2019 2018 FY
2016 $5,305,070 +$2,405,766 +83% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2018 2017 FY
2015 $2,899,304 +$1,601,319 +123% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018 2017 FY
2014 $1,297,985 +$1,037,624 +399% 01 Jan 2014 31 Dec 2014 10-K 02 Mar 2017 2016 FY
2013 $260,361 01 Jan 2013 31 Dec 2013 10-K 08 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.